MedTrace Logo

Spanish-Language Smoking Cessation Trial

NCT02945787 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1417

Last updated 2022-11-04

Study results available
· View outcomes & findings →

Summary

Results of a recently completed National Cancer Institute (NCI) funded trial of an intervention, Forever Free: Stop Smoking for Good, revealed high efficacy throughout the 24- month follow-up period, further supporting the utility of extended self-help for promoting and maintaining tobacco abstinence. Investigators have recognized that wide-scale implementation, and therefore public health impact, would be enhanced by the availability of a Spanish-language version to reach the largest and fastest growing ethnic minority population of smokers.

The goal of this study is to address this gap by testing a Spanish-language version of the validated self-help smoking cessation intervention. If demonstrated effective, the proposed intervention would represent an easily disseminable and low-cost intervention with significant public health impact for Hispanic/Latino smokers throughout the United States. The aims of this project are to test the efficacy of a Spanish-language version of a validated, extended self-help intervention for smoking cessation among Spanish-speaking smokers against usual care control. Participants (N = 1400) recruited nationally will be randomized to the two arms.

Conditions

  • Smoking Cessation

Interventions

BEHAVIORAL

Spanish-Language Version of the Stop Smoking for Good

Participants in the first arm will receive the Spanish-language version of the Stop Smoking for Good (SS-SP) intervention distributed over 18 months.

BEHAVIORAL

NCI-Produced Spanish-language Self-help Booklet

Participants in the second arm will receive a single, credible, NCI-produced Spanish-language self-help booklet.

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Florida Department of Health

    collaborator OTHER_GOV

  • H. Lee Moffitt Cancer Center and Research Institute

    lead OTHER

Principal Investigators

  • Thomas Brandon, Ph.D. · H. Lee Moffitt Cancer Center and Research Institute

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-10-24
Primary Completion
2020-07-31
Completion
2020-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02945787 on ClinicalTrials.gov